SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Astellas Pharma Inc. ALPMF OTC

Other OTC • Healthcare • Drug Manufacturers - General • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Astellas Pharma Inc. (ALPMF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $16.53. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $1.9T, +14%/yr average growth. Net income is $50.7B, growing at +31.5%/yr. Net profit margin is 2.7% (thin). Gross margin is 81.7% (+1.2 pp trend).

Balance sheet: total debt is $831.4B against $1.5T equity (Debt-to-Equity (D/E) ratio 0.55, moderate). Current ratio is 1.13 (adequate). Debt-to-assets is 24.9%. Total assets: $3.3T.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 33/100 (Fail), Moat 84/100 (Pass), Future ?/100 (Fail), Income 30/100 (Fail).

ALPMF SharesGrow Score Overview

73/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 84/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALPMF

ALPMF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

ALPMF: +14%/yr revenue is, +31.5%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

ALPMF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet ALPMF: Debt-to-Equity (D/E) ratio 0.55 (moderate), Current ratio is 1.13 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ALPMF: Gross margin is 81.7% (+1.2 pp trend), $30B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 84/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

ALPMF: Net profit margin is 2.7%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range8.4-17.6

Volume299

Avg Volume (30D)1.99K

Market Cap$29.61B

Beta (1Y)0.15

Dividend Yield$0.4569

Share Statistics

EPS (TTM)28.35

Shares Outstanding$1.8B

IPO Date2010-04-26

Employees14,754

CEONaoki Okamura

Financial Highlights & Ratios

Revenue (TTM)$1.91T

Gross Profit$1.56T

EBITDA$248.05B

Net Income$50.75B

Operating Income$41.04B

Total Cash$218.31B

Total Debt$831.43B

Net Debt$643.05B

Total Assets$3.34T

Price / Earnings (P/E)0.6

Price / Sales (P/S)0.02

Analyst Forecast

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINJP3942400007

Price Chart

ALPMF

Astellas Pharma Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - General

8.40 52WK RANGE 17.60

People Also View

Roche Holding AG

Roche Holding AG

AstraZeneca PLC

Chugai Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Daiichi Sankyo Company, Limited

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message